1007 / 1084
First line
Doublets or triplets?
Triplets only in patients with
high symptom burden
Stop using epirubicin
Ramucirumab-paclitaxel
Second line
What should be a standard?
Work in progress
PS 0-1; PFS > 3-6 months
Molecular classification
Do we have distinct treatment choices for
these different molecular pathways?
How can we address tumor heterogenity
when we design GC clinical trials?
Are all patients candidated to a second line therapy?
Methodological framework
Innovative clinical trial designs
03/28/2017